𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Individual treatment for malignant melanoma

✍ Scribed by Hiram C. Polk Jr.

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
298 KB
Volume
40
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis

Much has been learned in the recent decade about the predictable biologic behavior of cutaneous malignant melanoma. Indeed, such knowledge permits highly individualized treatment based on simple demographic data on the patient, location of the lesion, and its thickness according to the Breslow scale. The thoughtful surgeon may individualize his treatment according to the likely biologic behavior of the tumor, minimizing treatment morbidity while maintaining optimum results from primary and secondary surgical treatment.

πŸ“œ SIMILAR VOLUMES

Treatment of malignant melanoma
Treatment of malignant melanoma
✍ K. FortΓ½n; V. Hruban; V. HorΓ‘k πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 239 KB πŸ‘ 2 views
Treatment with levodopa and risk for mal
Treatment with levodopa and risk for malignant melanoma
✍ JΓΈrgen H. Olsen; Karina Tangerud; Lene Wermuth; Kirsten Frederiksen; SΓΈren Friis πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 64 KB

## Abstract A large follow‐up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case–control study of 45 patients with malignant melanoma, 97

Treatment of malignant melanoma by fast
Treatment of malignant melanoma by fast neutrons
✍ P. R. Blake; Mary Catterall; R. D. Errington πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 382 KB πŸ‘ 1 views

Fast neutron therapy has been used to treat 87 tumours of primary, recurrent or metastatic melanoma in 48 patients. Complete regression has been obtained in 71 percent of tumours and 91 per cent of all tumours were controlled for the remainder of the patients, lives. Median survival was 14.5 months;